X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-09-30 | BMEA | Hitchcock Michael J.M. | Dir | P - Purchase | $10.06 | +10,000 | 15,000 | +200% | +$100,600 | ||||||
2024-06-11 | BMEA | Valle Franco | CFO | P - Purchase | $4.43 | +12,509 | 42,500 | +42% | +$55,361 | ||||||
| M | 2023-05-31 | BMEA | A2A Pharmaceuticals, Inc. | 10% | S - Sale | $34.11 | -125,000 | 3,500,000 | -3% | -$4,263,915 | |||||
2023-05-12 | BMEA | A2A Pharmaceuticals, Inc. | 10% | S - Sale | $33.84 | -25,000 | 3,625,000 | -1% | -$846,000 | ||||||
| M | 2023-05-08 | BMEA | A2A Pharmaceuticals, Inc. | 10% | S - Sale | $34.30 | -250,000 | 3,650,000 | -6% | -$8,575,030 | |||||
2023-04-20 | BMEA | A2A Pharmaceuticals, Inc. | 10% | S - Sale | $29.12 | -200,000 | 3,900,000 | -5% | -$5,823,760 | ||||||
| A | 2023-03-31 | BMEA | A2A Pharmaceuticals, Inc. | 10% | S - Sale | $31.25 | -200,000 | 4,100,000 | -5% | -$6,250,000 | |||||
2023-03-31 | BMEA | A2A Pharmaceuticals, Inc. | 10% | S - Sale | $31.25 | -200,000 | 4,100,000 | -5% | -$6,250,000 | ||||||
| D | 2023-03-30 | BMEA | Chen Bihua | Dir, 10% | P - Purchase | $30.00 | +400,000 | 3,570,872 | +13% | +$12,000,000 | |||||
| A | 2021-04-15 | BMEA | Erdtmann Rainer M | Pres, COO, 10% | P - Purchase | $17.00 | +8,400 | 6,000 | -350% | +$142,800 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |